<DOC>
	<DOCNO>NCT01450215</DOCNO>
	<brief_summary>This : - A prospective , randomize , open , phase II , multi-centre , interventional study . Patients least PR receive lenalidomide 2nd line treatment MM recruit . - The patient randomize two group . Group R receive lenalidomide 25 mg/day p.o . continuously 21 day group Rb receive similar dose lenalidomide addition 40 mg dexamethasone p.o . day 1 , 8 , 15 22 every 28 day treatment cycle . Study include maximum 24 cycle include two consolidate cycle per patient .</brief_summary>
	<brief_title>Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide Second Line Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Inclusion Criteria subject must : 1 . Be least 18 year age 2 . Subjects must document diagnosis MM either refractory relapse refractory first line treatment disease define : Primary refractory Refractory Relapsed Refractory 3 . Subjects must undergo prior treatment one treatment line antimyeloma therapy . Induction therapy follow ASCT consolidation/maintenance consider one line.Have confirm diagnosis MM 4 . Have receive lenalidomide one prior treatment MM reach least partial response ( PR ) , accord IMWG criterion , include two consolidating cycle . Subjects experienced response least PR start treatment lenalidomide cortisone cycle . 5 . Have personally sign date legally effective write informed consent form prior admission study . 6 . Must willing able understand comply study requirement . 7 . Females childbearing potential must agree ongoing pregnancy test practice contraception . 8 . Male must agree practice contraception 1 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL Platelet count &lt; 75,000/ µL Creatinine Clearance &lt; 45 mL/min accord CockcroftGault formula Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL 2 . ECOG performance status &lt; 4 . 3 . Individuals stemcell transplant 2nd line treatment MM 4 . Individuals take experimental drug participate clinical trial within 30 day prior screen . 5 . Individuals significant psychiatric illness clinically significant acute/chronic uncontrolled medical condition might affect experience myeloma symptom ability describe . 6 . Pregnant lactating female . 7 . Any clinically significant medical disease condition , Investigator´s opinion , may interfere protocol adherence subject´s ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Relapsed refractory Multiple Myeloma</keyword>
</DOC>